In February 2026 Allderma was sold to Avia Pharma, a European consumer healthcare platform owned by healthcare PE fund Impilo.
We have been invited to pitch for the sales mandate of Allderma https://allderma.se/ , a Swedish consumer healthcare company. Allderma has a strong position in certain segments of the Swedish dermatology market and mainly sells through pharmacies. Its strongest categories are dry scalp (https://daxxin.se/en/), nail fungus (https://terclara.se/), foot and hand warts (https://transversal.se/) and supplements for hair growth (https://www.baltex.se/varumarken/harkontroll). 2025 the company will have sales of approx. USD 15m with ca 17% EBITDA margin. During the last 4 years annual sales growth has been above 40% driven mainly by strong development of the dry scalp and nail fungus products. Around 90% of sales are generated in the Swedish market, but the company has recently started making inroads to the other Nordic markets. Especially the dry scalp and nail fungus products have good potential for expansion outside of the Nordics for a buyer with existing sales channels and market presence outside of the Nordics.
